Sharing analytical strategies to ensure omics datasets generate insights that are both truthful & actionable.
Bridging the gap from large-scale omics data generation to deep characterization of disease & treatment biomarkers.
Why PCA quality assessment workflows are critical to generating credible insights from high-dimensional omics data.
Why careful metadata preprocessing is key ensure insights derived from downstream analysis are accurate & reproducible.
How metabolite biomarkers can speed GLP-1 agonist time-to-market & drive competitive advantages via novel insights.
Highlighting the speed & depth of analyses that can be performed to inform drug development strategies.
Exploring key innovations have converged to transform the utility of proteomics in drug discovery & development.
Exploring the dark proteome and why it represents a critical, underexplored frontier in understanding and treating disease.
Approaches to address the complexities of metabolite profiling & maximize Tier 1 identification of small molecule biomarkers.
Featuring Sapient's platform as an omics technology advancing the discovery & implementation of dynamic biomarkers.
How multi-omics biomarker strategies are helping to realize the incredible therapeutic potential in these pipelines today.
PharmaShots profiles Sapient's high throughput proteomics and how our services fulfill market gaps for drug development.
